"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
There is no known antidote for overdoses of VALSTAR (valrubicin) . The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms.
Myelosuppression is possible if VALSTAR (valrubicin) is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder rupture/perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m². Dose limiting toxicities are leukopenia and neutropenia, beginning within 1 week of dose administration, with nadirs by the second week, and recovery generally by the third week. If VALSTAR (valrubicin) is administered when bladder rupture or perforation is suspected, weekly monitoring of complete blood counts should be performed for 3 weeks.
VALSTAR (valrubicin) is contraindicated in patients with known hypersensitivity to anthracyclines or polyoxyl castor oil.
Patients with concurrent urinary tract infections should not receive VALSTAR (valrubicin) .
VALSTAR (valrubicin) should not be administered to patients with a small bladder capacity, i.e., unable to tolerate a 75 mL instillation.
Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Valstar Information
Valstar - User Reviews
Valstar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.